SCHEMBL20190237

SCHEMBL20190237

COc1cccc(OC)c1NC(=S)c1nccs1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
ADRB2 P07550 1/20 0.41
MAPK1 P28482 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
GRM4 Q14833 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
ALOX12 P18054 1/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
SNCA P37840 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
PKM P14618 2/20 0.36
BRD4 O60885 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20207357 0.83 GAA (0.43) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20188746 0.83 GRM4 (0.52) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20207639 0.81 GAA (0.41) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20207359 0.80 GAA (0.41) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20189542 0.80 GAA (0.41) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20189540 0.80 GAA (0.41) GAARAB9ANPC1ADRB2MAPK1
SCHEMBL20189871 0.73 GAA (0.39) GAAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL21595538 0.72 NPC1 (0.59) GAARAB9ANPC1MAPK1MEN1
SCHEMBL20189397 0.71 KMT2A (0.49) KMT2ASMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL15484253 0.70 HPGD (0.51) GAAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS Amgen Inc. (US) 2019-09-25 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R GAA 4208/4885RAB9A 728/4885NPC1 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.